The overexpression of MYCN/MYC target genes in subtype 2 tumors, and the assignment of 10 out of 11 MYCN-amplified tumors to subtype 2 tumors (the remaining MYCN-amplified tumor being unclassified) suggest that MYCN/MYC play an important role in this subtype. This evidence concerns the gene MYC and neoplasm.